Artículos del autor

solaci

Day 2

REPRISE II: results obtained with the new valve according to VARC criteria

The objective was to evaluate the safety and efficacy of the Lotus Valve System to treat patients...
solaci -
Day 2

DEFLECT I: cerebral protection device in TAVI

Strokes after TAVI occur in between 3.8 and 6.7% of the cases, with new MRI lesions being...
solaci -
Day 2

DISCOVER: new low profile valve with little post-implant regurgitation

The objective of the study was to assess events after 30 days with the DirectFLOW Medical Valve...
solaci -
Day 2

JUPITER: transapical TAVI device

We evaluated 88 consecutive patients (at this phase) with severe aortic stenosis who received the second-generation device...
solaci -
Day 2

PROTAVI-C: Embolic protection during TAVI

Percutaneous aortic valve replacement (TAVI) is a new treatment option for patients that are inoperable or present...
solaci -
Day 2

BuMA stent: new sirolimus-eluting stent with bio-degradable polymer

Uncovered struts compromise re-endothelization and may induce thrombosis. The new stent approved in China and already used...
solaci -
Day 2

EXPAND: expanding the applications of bioresorbable platforms

There is little information about the use of bioresorbable vascular devices in patients with a reference diameter...
solaci -
Day 2

HATTRICK-OCT: biodegradable polymer struts coverage versus permanent

Late endothelialization of first generation pharmacological stents may predispose thrombosis. Both the drug and the polymer of...
solaci -